M&A Deal Summary |
|
|---|---|
| Date | 2016-10-12 |
| Target | Immunetics |
| Sector | Life Science |
| Buyer(s) | Oxford Immunotec Global |
| Deal Type | Add-on Acquisition |
| Deal Value | 6M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Medical Products |
| Employees | 260 |
| Revenue | 74M USD (2019) |
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company’s second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. Oxford Immunotec Global was founded in 2002 and is based in Abingdon, the United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: Massachusetts M&A | 2 of 2 |
| Country: United States M&A | 3 of 3 |
| Year: 2016 M&A | 2 of 2 |
| Size (of disclosed) | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-06-23 |
Imugen
Norwood, Massachusetts, United States Imugen, Inc. is a clinical and research laboratory located in Norwood, Massachusetts with over 25 years’ experience in the development and performance of specialized assays for tick-borne infections. Imugen is certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP) and is licensed as a clinical laboratory in Massachusetts, New York, Pennsylvania, Rhode Island and Maryland. |
Buy | $22M |
